Professional Documents
Culture Documents
Blood Bank II
Blood Bank II
Blood Bank II
D. Joe Chaffin, MD
Cedars-Sinai Medical Center, Los Angeles, CA
1) Permanent/indefinite deferrals
Infectious Risks
-High-risk behavior for AIDS
(IVDA, male-male sexual contact since 1977)
-Receiving money or drugs for sex
-Serologic positive for HIV, HBV, HCV, HTLV
-Viral hepatitis (any) after 11th birthday
-Transfusion of clotting factor concentrates (in hemophilia)
-History of Babesiosis or Chagas’ disease
-Growth hormone from human sources (pre-1985)
-Insulin from bovine sources
-Dura mater graft
Malignancies (see below)
-Leukemia or lymphoma
Teratogens
-Taking etretinate (Tegison)
2) Three year deferrals
Infectious Risks
-Recovered from malaria
-Immigrants from malaria-endemic countries
(after 5 consecutive years of living there)
Teratogens
-Taking acitretin (Soriatane)
3) One year deferrals
Infectious Risks
-Needle sticks or other contact with blood
-Sex contact with person with HIV or hepatitis
-Sex contact with person who used needles for drugs
-Rape victims
-Incarcerated > 72 consecutive hours
-Paying money/drugs for sex
-Blood transfusion (allogeneic); including plasma/clotting
factors in nonhemophiliacs
-Allogeneic transplant of organ/skin/bone
-Living with person with active hepatitis
(exception: Asymptomatic Hepatitis C)
-Receiving Hepatitis B Immune Globulin (HBIG)
-Tattoos/piercings (unless by regulated entity)
-Travel to malaria-endemic areas for residents of non-endemic
countries (>24 hrs, < 5 years)
-Diagnosed with syphilis or gonorrhea
-Non-prophylactic rabies vaccination
-“Travel” to Iraq
Immunization Deferrals
Four Weeks: Rubella
Varicella
Two Weeks: Measles
Mumps
Oral polio
Yellow fever
Oral typhoid
No Deferral: Anthrax
Cholera
DPT
Hepatitis A
Hepatitis B
Influenza
Lyme disease
Meningococcus
Pneumococcus
Polio (injection)
RMSF
Typhoid (injection)
12 Months: Unlicensed vaccines
c) Smallpox vaccination
i) Deferrals based on presence/ absence of
vaccine scab and post-vaccination symptoms
ii) No symptoms: defer until scab falls off or 21
days, whichever is longer
iii) With symptoms: defer until 14 days after
symptoms resolve
b. Time limit
1) < 10 minutes best, but no upper limit defined
a) Beyond 15 minutes, plasma/PLTs not made
5. Testing donor blood (Collection center)
a. ABO grouping
b. RhD typing
1) Weak D required if D negative (see BBI)
c. Antibody detection (“screen”)
1) Unexpected (non-ABO) antibodies in donor serum
2) AABB Standards: If positive, may still use blood,
but only to make products with minimal plasma
(i.e., RBCs ok; can’t make FFP, cryo, or platelets).
3) Label must reflect any positive results that are
identified as clinically significant antibodies.
4) Reality: Most hospitals don’t want this blood
d. Infectious disease screening (as of 2/2014); see
appendix and further details starting on page 13
1) Hepatitis B Tests
a) HbsAg
b) Anti-HBc
c) HBV nucleic acid test (HBV NAT)
2) Hepatitis C Tests:
a) Anti-HCV
4) HCV NAT
3) HIV tests:
a) Anti-HIV-1/2
b) HIV-1 NAT
4) Other tests:
a) Anti-HTLV-I/II
b) West Nile virus NAT
c) Anti-Trypanosoma cruzi (Chagas’ disease)
d) Serologic test for syphilis
6. Testing donor blood (Transfusion Service)
a. Requires confirmation of collection center’s work
b. Confirmatory tests:
1) ABO grouping (RBC grouping only)
2) RhD-negative confirmation
a) Direct testing only of units labeled as D–
b) Weak D testing not required (done already)
c) Units labeled as D+ do not require confirmation
3) Antibody screen and infectious disease screening on
donor units do not require confirmation
B. Donor reactions
1. Vasovagal reactions
a. Most common reaction (2.5% of healthy donors)
1) Most common in young, first-time female donors
2) Can be seen in any donor, though
3) Can happen before, during, or after donation
3. Hepatitis C virus
a. RNA virus
b. 0.5-1.0% of US blood donors
c. Both cellular and plasma components transmit.
d. Strong association with chronic hepatitis (75%),
cirrhosis, and hepatocellular carcinoma (>HBV)
1) Currently #1 reason for hepatic transplant in the US.
2) Initial presentation mild or asymptomatic
e. Donor testing (see appendix)
1) Antibody test is anti-HCV (EIA/ChLIA)
a) Window period with antibody test: 70-80 days
APPENDIX I
Blood Donor Infectious Disease Screening Tests
Agent Screening Test(s) Confirmatory Test(s) Discussion
HIV Anti-HIV 1/2 EIA/ChLIA: Western blot RR anti-HIV + Reactive HIV NAT = permanent
(EIA/ChLIA) (WB) or IFA for HIV-1 deferral
HIV-1 NAT (PCR, EIA/ChLIA: HIV-2 EIA RR anti-HIV + WB neg/indeterm + NR HIV NAT =
TMA) required after reactive indefinite deferral (may try to re-enter in 8 weeks)
anti-HIV-1/2 RR anti-HIV + positive WB = permanent deferral
NAT: Individual donor NR anti-HIV + reactive HIV NAT = indefinite deferral
NAT (if not done) (may try to re-enter in 8 weeks)
HCV Anti-HCV EIA/ChLIA: Repeat EIA RR anti-HCV + reactive HCV NAT = permanent
(EIA/ChLIA) with another EIA (under deferral
HCV NAT FDA variance) or RR anti-HCV + RIBA neg/indeterm (unconfirmed
(PCR/TMA) approved supplemental supplement) + NR HCV NAT = indefinite deferral
NAT versions (may try to re-enter in 6 months)
RIBA for anti-HCV EIA RR anti-HCV + positive RIBA (confirmed
(not currently available) supplement) = permanent deferral
NAT: Individual donor RR anti-HCV + RR anti-HCV (different platform) OR
NAT (if not done) positive supplemental NAT = permanent deferral
NR anti-HCV + reactive HCV NAT = indefinite
deferral (may try to re-enter in 6 months)
HBV HBsAg EIA/ChLIA: RR anti-HBc x 1 = no deferral
(EIA/ChLIA) Neutralization for HBsAg, RR anti-HBc x 2 = permanent deferral
Anti-HBc none for anti-HBc RR anti-HBc + RR HBsAg = permanent deferral
(EIA/ChLIA) NAT: Individual donor RR HBsAg + confirmed neutralization = permanent
NAT HBV NAT (if not done) deferral
(Required 2013) RR HBsAg + nonconfirmed neutralization = retest in >
8 weeks
NAT HBV reactive + RR HBsAg (confirmed
neutralization) = permanent deferral
HTLV-I/II Anti-HTLV-I/II None licensed Reactive anti-HTLV-I/II x 1 = no deferral
(EIA/ChLIA) Reactive anti-HTLV-I/II x 2 = permanent deferral
Syphilis (T. Many (hemag- Usually FTA or TP-PA Reactive screen + negative confirm = no definite
pallidum) glutination, EIA, deferral (though many will defer)
RPR) Reactive screen + reactive confirm = at least 1 year
deferral (after treatment)
West Nile WNV NAT Individual donor NAT (if Reactive NAT = 120 day deferral (if asymptomatic)
Virus (PCR/TMA) not done)
Chagas T. cruzi Enzyme Strip Assay Reactive EIA = permanent deferral
Disease (T. EIA/ChLIA (ESA); FDA approved ESA and RIPA results only for counseling
cruzi) Many use RIPA (not FDA No re-entry currently
approved) Testing may be once per lifetime only
RR: Repeat reactive
EIA/ChLIA: Enzyme immunoassay or chemiluminescent immunoassay
PCR/TMA: Polymerase chain reaction or transcription-mediated amplification (available US NAT
platforms)
IFA: Immunofluoresence assay
RIBA: Recombinant immunoblot assay (NOTE: RIBA has been discontinued by manufacturer, and all
protocols using it are unavailable; see strikethrough text above)
FTA: Fluorescent treponemal antibody
TP-PA: Treponema pallidum particle agglutination
RIPA: Radioimmunoprecipitation assay
RPR: Rapid plasma reagin
Sources: AABB Technical Manual, 17th ed, www.fda.gov
Please tell us if you are now taking or if you have EVER taken any of these medications:
Proscar (finasteride) usually given for prostate gland enlargement
Avodart, Jalyn (dutasteride) usually given for prostate enlargement
Propecia (finasteride) usually given for baldness
Accutane, Absorica (Amnesteem, Claravis, Sotret, isotretinoin) usually given for severe
acne
Soriatane (acitretin) – usually given for severe psoriasis
Tegison (etretinate) – usually given for severe psoriasis
Growth Hormone from Human Pituitary Glands used usually for children with delayed
or impaired growth
Insulin from Cows (Bovine, or Beef, Insulin) used to treat diabetes
Hepatitis B Immune Globulin – given following an exposure to hepatitis B.
NOTE: This is different from the hepatitis B vaccine which is a series of 3 injections
given over a 6 month period to prevent future infection from exposures to hepatitis B.
Plavix (clopidogrel) and Ticlid (ticlopidine) – inhibits platelet function; used to reduce the
chance for heart attack and stroke.
Feldene – given for mild to moderate arthritis pain
Experimental Medication or Unlicensed (Experimental) Vaccine – usually associated
with a research protocol